Literature DB >> 29782570

EGFR targeted therapy for lung cancer: are we almost there?

Giulio Metro1.   

Abstract

Entities:  

Year:  2018        PMID： 29782570      PMCID： PMC5943235          DOI： 10.21037/tlcr.2018.03.11

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  10 in total

1.  Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Authors:  Jessica J Lin; Stephanie Cardarella; Christine A Lydon; Suzanne E Dahlberg; David M Jackman; Pasi A Jänne; Bruce E Johnson
Journal:  J Thorac Oncol       Date:  2015-12-25       Impact factor: 15.609

Review 2.  Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.

Authors:  Sarah Burdett; Jean Pierre Pignon; Jayne Tierney; Helene Tribodet; Lesley Stewart; Cecile Le Pechoux; Anne Aupérin; Thierry Le Chevalier; Richard J Stephens; Rodrigo Arriagada; Julian P T Higgins; David H Johnson; Jan Van Meerbeeck; Mahesh K B Parmar; Robert L Souhami; Bengt Bergman; Jean-Yves Douillard; Ariane Dunant; Chiaki Endo; David Girling; Harubumi Kato; Steven M Keller; Hideki Kimura; Aija Knuuttila; Ken Kodama; Ritsuko Komaki; Mark G Kris; Thomas Lad; Tommaso Mineo; Steven Piantadosi; Rafael Rosell; Giorgio Scagliotti; Lesley K Seymour; Frances A Shepherd; Richard Sylvester; Hirohito Tada; Fumihiro Tanaka; Valter Torri; David Waller; Ying Liang
Journal:  Cochrane Database Syst Rev       Date:  2015-03-02

3.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Authors:  Karen Kelly; Nasser K Altorki; Wilfried E E Eberhardt; Mary E R O'Brien; David R Spigel; Lucio Crinò; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Philip C Hoffman; Sergey V Orlov; Piotr Serwatowski; Jiuzhou Wang; Margaret A Foley; Julie D Horan; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

4.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

5.  Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Authors:  Aadel A Chaudhuri; Jacob J Chabon; Alexander F Lovejoy; Aaron M Newman; Henning Stehr; Tej D Azad; Michael S Khodadoust; Mohammad Shahrokh Esfahani; Chih Long Liu; Li Zhou; Florian Scherer; David M Kurtz; Carmen Say; Justin N Carter; David J Merriott; Jonathan C Dudley; Michael S Binkley; Leslie Modlin; Sukhmani K Padda; Michael F Gensheimer; Robert B West; Joseph B Shrager; Joel W Neal; Heather A Wakelee; Billy W Loo; Ash A Alizadeh; Maximilian Diehn
Journal:  Cancer Discov       Date:  2017-09-24       Impact factor: 39.397

6.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

Review 7.  Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.

Authors:  Luca Toschi; Sabrina Rossi; Giovanna Finocchiaro; Armando Santoro
Journal:  Ecancermedicalscience       Date:  2017-11-30

8.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

9.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245

10.  Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Authors:  Audrey Mauguen; Jean-Pierre Pignon; Sarah Burdett; Caroline Domerg; David Fisher; Rebecca Paulus; Samithra J Mandrekar; Chandra P Belani; Frances A Shepherd; Tim Eisen; Herbert Pang; Laurence Collette; William T Sause; Suzanne E Dahlberg; Jeffrey Crawford; Mary O'Brien; Steven E Schild; Mahesh Parmar; Jayne F Tierney; Cécile Le Pechoux; Stefan Michiels
Journal:  Lancet Oncol       Date:  2013-05-14       Impact factor: 41.316
  10 in total
  2 in total

1.  Metformin sensitizes hypoxia-induced gefitinib treatment resistance of HNSCC via cell cycle regulation and EMT reversal.

Authors:  Xiteng Yin; Zheng Wei; Chuanhui Song; Chuanchao Tang; Wenguang Xu; Yufeng Wang; Junqi Xie; Zitong Lin; Wei Han
Journal:  Cancer Manag Res       Date:  2018-11-19       Impact factor: 3.989

2.  Novel 4-arylaminoquinazolines bearing N,N-diethyl(aminoethyl)amino moiety with antitumour activity as EGFRwt-TK inhibitor.

Authors:  Yaling Zhang; Li Chen; Xiabing Li; Li Gao; Yunxia Hao; Baolin Li; Yaping Yan
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.